| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 12, 2021 | Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults | |
| Aug 11, 2021 | Stand Up To Cancer And Jazz Pharmaceuticals Collaborate To Fund Catalyst Research On Hard-To-Treat Cancers | $4 Million Research Collaboration to Explore New Treatment Options for Pediatric Solid Tumors or RAF, RAS Mutated Tumors
Stand Up To Cancer (SU2C) and Jazz Pharmaceuticals plc (JAZZ) announce a three-year, $4 million research collaboration ... |
| Aug 3, 2021 | Jazz Pharmaceuticals Announces Second Quarter 2021 Financial Results | |
| Jul 29, 2021 | Onera raises €10.5M in Series B funding | Onera raises €10.5M in Series B funding
29 Jul 2021
Onera Health, a leader in sleep diagnostic and monitoring solutions, closed €10.5M in Series B funding. The round was led by Innovation Industries in close collaboration with Invest-NL a... |
| Jul 13, 2021 | Jazz Pharmaceuticals Announces Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Investor Webcast on July 20, 2021
USA - English USA - English | |
| Jun 25, 2021 | Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution | |
| Jun 17, 2021 | Jazz Pharmaceuticals Updates 2021 Financial Guidance to Include Recently Acquired GW Pharmaceuticals plc | |
| Jun 9, 2021 | Jazz Pharmaceuticals Presents 18 Abstracts in Sleep Medicine at SLEEP 2021 | |
| May 5, 2021 | Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc | |
| May 4, 2021 | Jazz Pharmaceuticals Announces First Quarter 2021 Financial Results | |
| Apr 29, 2021 | Jazz Pharmaceuticals Announces Closing of Senior Secured Notes Offering | |
| Apr 22, 2021 | Jazz Pharmaceuticals Prices $1.5 Billion Senior Secured Notes Offering | |
| Apr 20, 2021 | Jazz Pharmaceuticals Announces Proposed Private Offering of Senior Secured Notes | |
| Apr 20, 2021 | Jazz Pharmaceuticals Presents Phase 3 Study Results of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia at 2021 American Academy of Neurology Annual Meeting | |
| Apr 12, 2021 | Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Idiopathic Hypersomnia | |
| Mar 30, 2021 | Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients | |
| Mar 22, 2021 | Jazz Pharmaceuticals Announces Participation at the 10th Annual J.P. Morgan Napa Valley Forum | |
| Mar 18, 2021 | Jazz Pharmaceuticals and Hypersomnia Foundation Launch Campaign to Increase Understanding and Awareness of Idiopathic Hypersomnia | |
| Feb 23, 2021 | Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results | DUBLIN, Feb. 23, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2020 and provided financial guidance for 2021.
"In 2020, we made meaningful progres... |
| Feb 23, 2021 | Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results | |
| Feb 23, 2021 | Jazz Pharmaceuticals Announces Participation at Cowen 41st Annual Healthcare Conference | |
| Feb 16, 2021 | Jazz Pharmaceuticals Completes Submission of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia | |
| Feb 3, 2021 | Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader | |
| Jan 4, 2021 | Jazz Pharmaceuticals Announces Participation in the 39th Annual J.P. Morgan Healthcare Conference | |
| Dec 21, 2020 | Jazz Pharmaceuticals Announces Initiation of Biologics License Application Submission for JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | |
| Nov 10, 2020 | Jazz Pharmaceuticals Announces Participation at Jefferies Virtual London Healthcare Conference | |
| Nov 2, 2020 | Jazz Pharmaceuticals Announces Third Quarter 2020 Financial Results | |
| Oct 20, 2020 | Jazz Pharmaceuticals Announces SLEEP Publication of Phase 3 Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Study in Cataplexy or Excessive Daytime Sleepiness in Patients with Narcolepsy | |
| Oct 19, 2020 | Jazz Pharmaceuticals Announces Webcast for Xywav Investor Update | |
| Oct 8, 2020 | Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia | |
| Sep 17, 2020 | Jazz Pharmaceuticals Launches Initiative to Help Educate People Living with Rare Form of Leukemia | |
| Sep 15, 2020 | Jazz Pharmaceuticals Announces New Sleep Health Collaboration | |
| Aug 27, 2020 | Jazz Pharmaceuticals to Present New Data on Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Sunosi® (solriamfetol) at Virtual SLEEP 2020 | |
| Aug 13, 2019 | Jazz Pharmaceuticals Acquires Cavion, for Up To $312.5M | Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company dedicated to developing life-changing medicines for people with limited or no options, acquired Cavion, Inc., a Charlottesville, VA and Cambridge, MA-based clinical... |
| Apr 23, 2019 | Onera Health Raises $9.3M to Pilot Medical Grade Sleep Diagnostics Patch | Onera Health Inc., a Palo Alto, CA-based sleep diagnostic solutions and services provider announced it raised $9.3 million in Series A funding led by Jazz Pharmaceuticals, imec.xpand, as well as other investors including imec and BOM. The d... |